Kamada (KMDA) said Tuesday that its operations and manufacturing in Israel are continuing, and global product availability remains unaffected by recent events in the Middle East.
The biopharmaceutical company said its shipments from Israel may be temporarily affected by the current closure of Israeli airspace but that its distribution centers outside Israel and international partners have sufficient level of products to meet client demands.